Nigro, A., Ricciardi, L., Salvato, I., Sabbatino, F., Vitale, M., Crescenzi, M. A., . . . Dal Col, J. (2020). Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC. Front Immunol.
シカゴスタイル引用形Nigro, Annunziata, et al. "Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC." Front Immunol 2020.
MLA引用形式Nigro, Annunziata, et al. "Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC." Front Immunol 2020.
警告: この引用は必ずしも正確ではありません.